Nomura analyst Christopher Marai maintained a Buy rating on Voyager Therapeutics Inc (VYGR) on August 9 and set a price target of $37. The company’s shares closed last Monday at $20.11.
“Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future.”
According to TipRanks.com, Marai is a 4-star analyst with an average return of 7.0% and a 49.3% success rate. Marai covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Protagonist Therapeutics, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is a Moderate Buy with an average price target of $31.40, a 55.4% upside from current levels. In a report issued on August 9, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.79 and a one-year low of $7.76. Currently, Voyager Therapeutics Inc has an average volume of 442.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.